← Leaderboards
Jinfa Du
Pharmasset, Inc.
$559,492
Attributed
$559,492
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $195K · FY2005–06$200K$150K$100K$50K$0
'05
'06
Funding mix
By agency
NIH$559,492 · 2
By mechanism
R01$384,232 · 1
R43$175,260 · 1
Top collaborators
No co-investigators on record.
Most similar at Pharmasset, Inc.
Same institution · by research overlap
- Kyoichi A Watanabe$447,034
- Krzysztof W Pankiewicz$725,009
- Michael J Otto$289,584
- Lieven J Stuyver$162,200
Others in their field
Top investigators on “Tissue /Cell Culture”
- James R Gaines · University Of Hawaii At Manoa$24,999,553
- Jay B Jackson · Johns Hopkins University$22,308,100
- C Ronald Kahn · Joslin Diabetes Center$12,500,002
- George Stamatoyannopoulos · University Of Washington$11,744,799
- Laurie H Glimcher · Dana-Farber Cancer Inst$10,563,992
- Peter Karl Sorger · Massachusetts Institute Of Technology$9,821,548
Research focus
Tissue /Cell CultureDrug Design /Synthesis /ProductionLaboratory MouseRepliconChemical SynthesisSite Directed MutagenesisAntiviral AgentsHepatitis C VirusDrug Screening /EvaluationMacaca FascicularisNucleoside AnalogNucleosidesPharmacokineticsPolymerase Chain ReactionPurinesSds Polyacrylamide Gel ElectrophoresisStereoisomerAcetylationWestern BlottingsBiotherapeutic AgentCytosineCytotoxicityDosageEnzyme Inhibitors
Grant awards (4)
2'-AND/OR 4'-C-MODIFIED NUCLEOSIDES AS ANTI-HCV AGENTS$1
R01 · FY2006 · DK · contact PI
2'-AND/OR 4'-C-MODIFIED NUCLEOSIDES AS ANTI-HCV AGENTS$194,954
R01 · FY2005 · DK
2'-AND/OR 4'-C-MODIFIED NUCLEOSIDES AS ANTI-HCV AGENTS$189,277
R01 · FY2004 · DK
DIOXOLANE NUCLEOSIDES AS ANTIVIRAL AGENTS$175,260
R43 · FY2003 · AI